chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually have chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable & treatable disease.

Drug Information

Indication: Regular treatment of COPD including chronic bronchitis & emphysema. Accuhaler Regular treatment of asthma...

Indication: Long-term maintenance treatment of bronchospasm & dyspnoea associated w/ COPD.

Indication: Maintenance bronchodilator treatment for symptomatic relief of COPD. Add-on maintenance bronchodilator treatme...

Striverdi Respimat
olodaterol

Indication: Maintenance treatment in patients w/ chronic obstructive pulmonary disease (COPD).

Indication: Bronchodilator for maintenance treatment of bronchospasm associated w/ COPD including chronic bronchitis &...

Indication: Bronchodilator for maintenance treatment of bronchospasm, associated w/ COPD, including chronic bronchitis, em...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Dosage: Symptomatic treatment of acute asthma episodes 1 puff stat. If breathing has not improved after 5 min, a 2nd p

Indication: Management of reversible bronchospasm associated w/ obstructive airway disease in patients who require more th...

1  /  14
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 21 Jul 2017
Deficiency in vitamin A (<200 µg/L) may predict the risk of incident tuberculosis (TB) in individuals with household exposure to a person with TB, a recent study has found.
14 Mar 2016
Delamanid may be a potent treatment regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) patients, based on a study.
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Dr Joslyn Ngu, 16 Oct 2017

The main goal of the National Strategic Plan (NSP) for TB Control (2016 to 2020) is to reduce tuberculosis (TB) burden by ensuring universal access to timely and quality diagnosis and treatment of all types of TB, and preventing the development of drug resistant TB, says an expert.